It is time to conduct phase 3 clinical trials of sex hormones in MS -No
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Multiple sclerosis (MS) is a chronic autoimmune demyelinating disease of the central nervous system (CNS). It is the leading cause of non-traumatic neurologic disability among young adults, with an estimated prevalence of at least 500,000 people in the United States. It is a disease with distinct hormonal influences, both in female-predominant susceptibility and in gender and hormonal status-dependent variability of clinical activity and progression. Observational studies of exogenous oral contraceptives in humans historically suggested either a neutral or a possible therapeutic effect. This helps explain the renewed interest in sex hormones as potential MS treatments.
However, not every factor that may play a role in disease predisposition and course can easily become a therapeutic target. There are significant concerns to be addressed, before sex hormones can enter the mainstay of MS therapeutics. These include limited preliminary clinical data on efficacy, insufficient number of exposed patients, and a significant potential for life-altering or life-shortening side effects such as carcinogenesis, thrombogensis, and changes in reproductive behavior and plan, with the expected long-term use of these agents.
The data on estriol as disease modifying treatment (DMT) have been inconsistent, and the patient years of exposure to these therapeutics have been low. To date, there are two early phase clinical trials of estriol treatments in patients with relapsing-remitting MS (RRMS) and one phase 2 study on combined treatment with oral contraceptives as an add-on to platform therapy. [1] [2] [3] A randomized, double blind, placebo-controlled phase 2 RRMS trial has recently been completed and published. 2 Total number of patients randomized to 8 mg of daily estrogen for 24 months was 83 of 164 subjects. They also received daily norethindrone 0.7 mg for 2 weeks out of every 3 months and a platform injectable therapy, glatiramer acetate 20 mg daily. Overall, the clinical outcomes were mixed: there was no difference between the two groups in time to first relapse. The primary end point, annualized relapse rate (ARR) at 24 months, was 0.25 in the estriol group versus 0.37 in the placebo group (p = 0.077) with a pre-specified significance level of α = 0.1. This level was selected based on several trials in stroke, cancer, and amyotrophic lateral sclerosis (ALS) research that used lower power to detect treatment effect. Neither in early nor in late phase MS DMT trials had this statistic been used to support efficacy claims. There was no significant change in number or volume of T2 or gadolinium-enhancing lesions, or in total brain volume. While there was some beneficial effect on brain atrophy in the treated group in post hoc analysis, there was no difference in inflammatory magnetic resonance imaging (MRI) activity outcomes-a surprising result, considering prior studies, by these and other authors. 1, 3 In addition, a single-arm crossover design investigation of 10 subjects reported treatment with 8 mg of estriol and 100 mg of progesterone, daily, for 12 months. 1 Finally, a phase 2 study of daily ethinylestradiol 20 or 40 μg and desogestrel 125 μg, as add-on to interferon β-1-a SC injections was published. 3 Both studies suggested a beneficial effect on inflammatory activity by MRI, but not on clinical relapses. Significant reduction of gadolinium-enhancing lesions and favorable immunomodulatory profile was seen in the treated subjects. Unfortunately, this MRI outcome was not replicated in a subsequent study.
A trial of 100 mg of daily testosterone treatment in 10 men with RRMS reported favorable effects on cognition and brain atrophy, but not on MRI measures of inflammatory activity. 4 No additional testosterone treatment trials have been published.
To date, 93 RRMS patients in total have been exposed to estriol through randomized phase 2 trials, and 99 RRMS patients have been exposed to ethinylestradiol through a phase 2 trial. In comparison with other phase 2 RRMS clinical trials, these numbers are low. To illustrate, phase 2 clinical trials for daclizumab included 208 subjects in active treatment arm; four natalizumab phase 2 trials included a total of 575 subjects randomized to active treatment; alemtuzumab phase 2 trial had 334 subjects randomized to treatment group. Significant and, often, unanticipated side effects were detected through these and later stage clinical trials as well as through post-marketing surveillance. In one instance, this led to removal of a DMT from the market and discontinuation of clinical development program (daclizumab), while in other instances, "black box" warnings and risk mitigation programs have been put in place (natalizumab and alemtuzumab). Both of these agents have proven superior clinical efficacy throughout clinical trials, justifying ongoing availability for clinical use.
While no significant adverse events were reported over the duration of the two estriol trials, chronic exposure to sex steroids, as would be required for a standard DMT in MS, remains a concern.
Exogenous estrogen therapy has been associated with increased risk of breast cancer, particularly, in women receiving estrogen-and progesterone-based hormone replacement therapy or oral contraception (OCP). [5] [6] [7] Increased duration of exposure to high levels of estrogen (as seen in nulliparous women, women with early menarche, late menopause) have also been linked to increased risk of breast cancer. In addition, estrogen has been linked to increased risk of endometrial cancer and thromboembolism. [8] [9] [10] While the majority of this risk is linked to estradiol or E2 form of estrogen, there is no enough data on the long-term safety of estriol (E3). Pre-clinical data suggest that E3 may also have potential carcinogenic effects. 11 Overall, there is the abundance of literature suggesting significant harms to long-term unopposed estradiol, or combined OCP use, and there is the lack of knowledge on the risks of long-term unopposed estriol use.
In summary, we believe that it is premature to invest substantial time and resources to phase 3 clinical trials of sex hormones in MS:
• • There are insufficient and inconsistent efficacy results from early phase clinical trials. • • There is a low number of MS patient-years of sex steroids exposures from current trials, limiting our ability to detect a signal for adverse outcome. • • Long-term exposure to sex steroids has a high potential for significant side effects and could alter patients' reproductive plans. • • Sex-specific hormonal treatments would have limited therapeutic applicability to wide and diverse groups of MS patients.
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The relationship between sex-related factors and multiple sclerosis (MS), nowadays widely recognized, has led to the idea that sex hormones, easily available at low cost, could be promising therapeutic solutions for MS. However, their putative impact is not univocal: the two main oestrogen receptors (ERα and ERβ) can act synergistically or antagonistically depending on the tissue and in MS they could modulate both inflammation (through ERα activation on peripheral and central nervous system (CNS) resident immune cells and astrocytes) and repairing pathways (through ERβ activation on oligodendrocytes, astrocytes and monocytes). 1 By contrast, progesterone and androgens have not been shown to reverse inflammation but both demonstrated potential to enhance myelin repair in experimental models. 2, 3 Supporting the pros of pushing sex hormones towards phase 3, R Voskul points out that estriol is to date the most promising candidate that could be used as a disease-modifying therapy (DMT). Its previous evaluation in pilot phase 2 studies described a beneficial impact on magnetic resonance imaging (MRI) and relapse rate and doses needed to reach clinical effects are well tolerated (a condition not achieved for estradiol). The preferential binding to ERβ also suggests a safer oncological risk profile. However, as discussed by Houtchens and Desai, the total number of subjects included remains very low, and the results were not fully consistent across studies. Moreover, the putative consequences of long-term exposure to sex hormones, regarding possible oncological or thromboembolism risk, are not yet well known. To further characterize the potential of estriol to be used as a DMT, there is still a need to demonstrate equivalence or advantage over available drugs, regarding not only cost, but also efficacy and/or risk, through a larger comparative trial. However, due to their major cost, phase 3 trials are unlikely to be sponsored at this stage. To circumvent this blocking issue, comparative phase 2 trials may represent a promising solution: meta-analysis of past therapeutic trials in MS convincingly showed that the efficacy of immune-active drugs on MRI-based metrics such as T2 lesions or gadolinium-enhanced lesions in phase 2 is strongly predictive of the level of efficacy on relapse rate in phase 3, 4 opening the perspective of comparative phase 2 studies based on MRI metrics. Even so, assessing safety profile would still require larger cohorts, such as close post-marketing surveillance.
Sex hormones were also shown to promote myelin repair and neuroprotection in animal models, a yet unmet need in MS. 1, 3 However, none has really reached the level of evidence needed to start a phase 3 trial in this indication. An increasing number of repurposed compounds, including hormones, are nowadays candidate for repair trials in MS, but the optimal design to validate their efficacy remains challenging, as we still lack a sensitive and specific measure of remyelination. Pilot repair studies have mainly focused on the optic nerve, an anatomic region that has intrinsically low remyelination capacities. Imaging outcomes such as myelin positron emission tomography (PET) or advanced MRI sequences specific for myelin may enable to quantify remyelination with an improved sensitivity. 
